Minimal risk is where the probability and magnitude of harm or discomfort anticipated in the research are not greater than those ordinarily encountered in daily life, or during the performance of routine physical or physiological examinations or tests. The determination of the type of review is made by CIRB.
click here to view the Submission Workflow.
Full Board Review (New Applications/ Amendments/ Renewals/ Re-table studies)
The CIRB review board meets once a month. The submission deadline for Full Board Reviews (studies with more than minimal risk and major amendments) is the first working day of each month.*
For new applications, the Principal Investigator should submit with sufficient lead time for the Research Development Office check (if applicable), Department Representative and Institutional Representative to endorse prior to the first working day of the month. Submissions received by CIRB after the first working day may be tabled for the subsequent full board meeting.
For example, applications to be reviewed at the meeting in July 2015 must reach CIRB by 01 July 2015.
For CIRB's Full Board Review meeting schedule, please click here.
* With the exception of the month of December when there is no full board meeting.
Exemption and Expedited Review
Study applications or amendments (that involve minimal or less than minimal risks) may be submitted at any time.
All new applications under these categories accepted by the CIRB will be reviewed within 30 calendar days from the date of receipt. #
Exemption may be determined only by the CIRB. Determination of exemptions are not to be made by the investigator. Exemption waives the need for continuing review by the CIRB. However, changes to the study which may alter its exempt status must be resubmitted to the SingHealth CIRB for review. No human biomedical research may be initiated until formal written concurrence of exemption from the SingHealth CIRB has been obtained.
# This could vary depending on several factors such as the completeness, and quality of the application, complexity of the study and response time of the Investigator to CIRB's queries.
The minimum training requirement for SingHealth study team members is completing the Collaborative Institutional Training Initiative (CITI) Certificate. The required programme is Biomedical Research Investigators and Key Personnel. You could access the CITI programme from this link:
The minimum training for Principal Investigators and Site-Principal Investigators conducting clinical trials within SingHealth includes completing the Local Good Clinical Practice programme (local GCP) workshop (in addition to the current requirement for
CITI) when making a submission to the CIRB. For clinical trials that require a Clinical Trial Certificate from HSA, CIRB will not grant ethics approval for clinical trials applications until a receipt of proof for the Principal Investigator completion of the local GCP course is provided.